(Total Views: 221)
Posted On: 02/25/2018 9:49:34 AM
Post# of 72443
As to the dilution question, it is great that the developers/mgt of the company are also the largest stockholders so their interests are directly in line with small retail interests. Leo has done a remarkable job getting us to this point with less than 200MM shares and will continue to do so IMO.
As to the pipeline, I think we all know that we have 3 blockbusters on our plate that will all blossom into tremendous returns to stockholders. I would like to know (not saying there isn't) any company in biotech that had 3 such promising looking drugs at this stage of development for each at the same time. Our drugs seem to cover an enormous breadth of the medical scene and numerous multi billion dollar revenue streams. If the current prospects don't excite one, then they shouldn't be in biotech or shouldn't be investing period IMO.
As to the future, we have a good chance of getting shares in major BPs should the company be sold, possibly shares or heavy upfront payments with massive dividends down the line if we partner and receive hefty royalties for all sales down the line from partnered BPs, or nice upfront payments and royalties from one drug and greatly increased value for the other 2 should mgt decide to retain a platform or 2 for further development. I look at the above choices as a win-win-win for stockholders.
Bottom line: If we haven't found the golden ring in bio investments, things will sure have to change drastically to the negative in the future for such an outcome to occur. I don't see that happening with the safety profiles of the pipeline and how they have proven to work exactly as predicted by pre clinical results to date.
As to the pipeline, I think we all know that we have 3 blockbusters on our plate that will all blossom into tremendous returns to stockholders. I would like to know (not saying there isn't) any company in biotech that had 3 such promising looking drugs at this stage of development for each at the same time. Our drugs seem to cover an enormous breadth of the medical scene and numerous multi billion dollar revenue streams. If the current prospects don't excite one, then they shouldn't be in biotech or shouldn't be investing period IMO.
As to the future, we have a good chance of getting shares in major BPs should the company be sold, possibly shares or heavy upfront payments with massive dividends down the line if we partner and receive hefty royalties for all sales down the line from partnered BPs, or nice upfront payments and royalties from one drug and greatly increased value for the other 2 should mgt decide to retain a platform or 2 for further development. I look at the above choices as a win-win-win for stockholders.
Bottom line: If we haven't found the golden ring in bio investments, things will sure have to change drastically to the negative in the future for such an outcome to occur. I don't see that happening with the safety profiles of the pipeline and how they have proven to work exactly as predicted by pre clinical results to date.
(6)
(0)Scroll down for more posts ▼
